Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Minerva Neurosciences News

    2,49 $ -1,58% -0,04 $
    In : 2,3265 € | 24.04.24 16:21:30 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3DMH5
    ISIN: US6033802058
    US-Symbol: NERV
    Typ: Aktie

    Minerva Neurosciences News

    24.08.22 - PR Newswire
    Thinking about buying stock in Scisparc, Tufin Software Technologies, Farfetch, Energy Transfer, or Minerva Neurosciences?
    Thinking about buying stock in Scisparc, Tufin Software Technologies, Farfetch, Energy Transfer, or Minerva Neurosciences? PR Newswire
    24.08.22 - PR Newswire
    Thinking about buying stock in Bed Bath & Beyond, Bright Minds Biosciences, Farfetch, SoFi Technologies, or Minerva Neurosciences?
    Thinking about buying stock in Bed Bath & Beyond, Bright Minds Biosciences, Farfetch, SoFi Technologies, or Minerva Neurosciences? PR Newswire
    04.05.22 - GlobeNewswire
    Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
    Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022
    07.04.22 - GlobeNewswire
    Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
    Company to Host Webcast Wednesday, April 13, 2022 at 11am ET
    01.03.22 - GlobeNewswire
    Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates
    WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-​stage biopharmaceutical company focused on the development ...
    28.02.22 - GlobeNewswire
    Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
    Trial Results Confirm the Potential of Roluperidone To Treat Negative Symptoms and Improve Everyday Functioning in Patients with Schizophrenia
    08.11.21 - GlobeNewswire
    Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates
    Company to Host Conference Call Today at 8:30 a.m. ET
    03.11.21 - GlobeNewswire
    Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission
    WALTHAM, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-​stage biopharmaceutical company focused on the development of ...
    01.11.21 - GlobeNewswire
    Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
    Management to Host Conference Call
    11.10.21 - GlobeNewswire
    Minerva Neurosciences Announces Promotion of Geoff Race to President
    Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA
    30.09.21 - GlobeNewswire
    Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
    Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration
    08.09.21 - GlobeNewswire
    Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development
    Dr. Jay Saoud, Head of Research & Development, to retire from his current role and transition to an advisory role in which he will continue to support the preparation and planned ...
    02.08.21 - GlobeNewswire
    Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates
    WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-​stage biopharmaceutical company focused on the development of ...
    26.07.21 - GlobeNewswire
    Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021
    Management to host conference call
    10.06.21 - GlobeNewswire
    Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
    WALTHAM, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-​stage biopharmaceutical company focused on the development ...
    28.05.21 - GlobeNewswire
    Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference
    WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-​stage biopharmaceutical company focused on the development of ...
    19.05.21 - PR Newswire
    Thinking about buying stock in LightPath Technologies, Minerva Neurosciences, Cerecor, Eloxx Pharmaceuticals, or Soleno Therapeutics?
    Thinking about buying stock in LightPath Technologies, Minerva Neurosciences, Cerecor, Eloxx Pharmaceuticals, or Soleno Therapeutics? PR Newswire
    12.05.21 - PR Newswire
    Thinking about buying stock in Minerva Neurosciences, Fubotv, Lucira Health, Biomerica, or Comstock Mining?
    Thinking about buying stock in Minerva Neurosciences, Fubotv, Lucira Health, Biomerica, or Comstock Mining? PR Newswire
    12.05.21 - GlobeNewswire
    Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
    Top-line results from the open-​label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement ...
    11.05.21 - GlobeNewswire
    Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension
    Key results Continuous improvement in negative symptoms as measured by Positive and Negative Syndrome Scale (PANSS) Marder Negative Symptom Factor Score (NSFS) ...

    Newssuche

    Videos

    newspaper
    24.04.24
    Technical Trading: AUD/USD mit Mega Chance
    AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »